logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2006 to 2007, where data are available [see all figures in this series...]

Part (i) Percentage positive for ever infected (aHBc)


Dark squares are samples with national coverage; blue triangle are samples with subnational (including local or regional) coverage.

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Italy and Austria are not prevalence of aHBc but prevalence of 'all HBV markers' as a proxy of aHBc prevalence.

Data for Lithuania and italy include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples not known).

Data for Belgium, Italy, Malta, The Netherlands, Slovenia and Slovakia is limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

Data for Poland and Luxembourg are from 2005.

Related links:

Statistical bulletin 2008: Figure INF-10 part (i).

For primary sources, study details and data before 2006, see Table INF-14, Table INF-15 and ....

See also ‘General notes for interpreting data’ on the Explanatory notes and help page


Reitox national focal points

(see the help page for information about formats etc.)

Page last updated: Thursday, 30 July 2009